Navigation Links
Jazz Pharmaceuticals Provides Update on FDA Advisory Committee Meeting For JZP-6 (Sodium Oxybate) in Fibromyalgia
Date:8/20/2010

PALO ALTO, Calif., Aug. 20 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the Joint Advisory Committee of the U.S. Food and Drug Administration (FDA), including the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, voted 20-2 that the benefit/risk balance did not support the approval of JZP-6 for the treatment of fibromyalgia with the currently proposed Risk Evaluation Mitigation Strategy (REMS).

"While we are disappointed with the recommendation of the Joint Advisory Committee, we plan to work closely with FDA on the continuing review of our new drug application (NDA)," said Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, Inc.  "We will carefully consider the input of the Committee as we seek to address the needs of fibromyalgia patients for new treatment options in a safe and responsible way."

Company to Host Teleconference on Monday, August 23

Jazz Pharmaceuticals will hold a teleconference and webcast for the investment community at 8:30 a.m. EDT (5:30 a.m. PDT) on Monday, August 23 to discuss the outcome of the FDA advisory committee meeting.  Investors may participate in the conference call by dialing 866.713.8566 in the U.S., or 617.597.5325 outside the U.S., and entering 35059911.  

A live webcast of the teleconference may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals (Nasdaq: JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see www.jazzpharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including statements related to future regulatory matters. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the uncertain and time-consuming regulatory approval process for

JZP-6 and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on August,11, 2010. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.  


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
2. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
4. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
5. Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million
6. Trubion Pharmaceuticals Inc. Reports Second-Quarter and First-Half 2010 Financial Results
7. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
8. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
9. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
10. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
11. Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017  Eli Lilly and Company (NYSE: ... $850 million in its U.S. operations in 2017. ... enterprise, including research laboratories, manufacturing sites, and general ... by demand for Lilly products, as well as ... targeting cancer, pain, diabetes and other unmet medical ...
(Date:3/24/2017)... Mar 24, 2017 The Board of Directors ... Annual Report 2016 including the complete 2016 Annual Accounts with ... on Nordic Nanovector,s website in the section Investor Relations/Reports and ... ... Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
(Date:3/23/2017)... 2017  Transportation Insight, a multi-modal lead logistics solutions ... management firm with expertise serving clients in the food ... Zaffarano was named a 2017 Food Logistics ... the only publication exclusively dedicated to covering the movement ... "Rick has brought to Transportation Insight a wealth ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier provider ... caring for those suffering from the full spectrum of disordered eating, announced today that ... professionals from nearly all 50 states and several countries converged on the Green Valley ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher Anahata ... and Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous ... spiritual journey during the Summer Solstice will also be her final international retreat, ...
(Date:3/24/2017)... PA (PRWEB) , ... March 24, 2017 , ... ... Oncology Nursing Society (ONS) wanted to create a communications platform that positions them ... this goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... ... ... Viewers who like to educate themselves on current issues and who enjoy ... societal issues tend to appreciate and love the "Informed" series, hosted by Rob Lowe. ... for causes around the world. , Running for charity has become a ...
Breaking Medicine News(10 mins):